

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**PATENT APPLICATION**

Box SEQ/1647 Dmt  
3-2-01  
#71A  
WD

Applicant(s): BOYLE, et al.

Serial No.: 09/613,591

Filed: JULY 10, 2000

For: COMBINATION THERAPY FOR TRADEMARK CONDITIONS  
LEADING TO BONE LOSS

Docket No.: A-378CIP5



Group Art Unit No.: 1647 MAR 01 2001

Examiner: R. Deberry TECH CENTER 1600/2900

**RECEIVED**

**RECEIVED**

FEB 22 2001

TECH CENTER 1600/2900

**RESPONSE TO  
NOTICE TO COMPLY AND AMENDMENT**

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:


This is in response to a "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures" dated January 17, 2001.

**AMENDMENT**

Please substitute the initial sequence listing with the attached amended sequence.

I hereby state that the paper copy and the computer readable form (CRF) of the "Sequence Listing" submitted herewith for the above-mentioned patent application are the same. The sequence listing submitted herewith contains no new matter.

Respectfully submitted,



Timothy J. Gaul  
Attorney for Applicant  
Registration No.: 33,111  
Phone: (805) 447-2688  
Date: February 16, 2001

Please send all future correspondence to:  
US Patent Operations/ TJG  
Dept. 430, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, DC 20231, on the date appearing below.

February 16, 2001

Date

Christina A. Yettress  
Signature